Abstract
In viral diseases T cells exert a prominent role in orchestrating the adaptive immune response and yet a comprehensive assessment of the T-cell repertoire, compared and contrasted with antibody response, after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is currently lacking. A prior population-scale study of the municipality of Vo’, Italy, conducted after the initial SARS-CoV-2 outbreak uncovered a high frequency of asymptomatic infected individuals and their role in transmission in this town. Two months later, we sampled the same population’s T-cell receptor repertoire structure in terms of both diversity (breadth) and frequency (depth) to SARS-CoV-2 antigens to identify associations with both humoral response and protection. For this purpose, we analyzed T-cell receptor and antibody signatures from over 2,200 individuals, including 76 PCR-confirmed SARS-CoV-2 cases (25 asymptomatic, 42 symptomatic, 9 hospitalized). We found that 97.4% (74/76) of PCR confirmed cases had elevated levels of T-cell receptors specific for SARS-CoV-2 antigens. The depth and breadth of the T-cell receptor repertoire were both positively associated with neutralizing antibody titers; helper CD4+ T cells directed towards viral antigens from spike protein were a primary factor in this correlation. Higher clonal depth of the T-cell response to the virus was also significantly associated with more severe disease course. A total of 40 additional suspected infections were identified based on T-cell response from the subjects without confirmatory PCR tests, mostly among those reporting symptoms or having household exposure to a PCR-confirmed infection. Taken together, these results establish that T cells are a sensitive, reliable and persistent measure of past SARS-CoV-2 infection that are differentially activated depending on disease morbidity.
Competing Interest Statement
RM Gittelman, TM Snyder, R Elyanow, S Dalai, I Kirsch, L Baldo have employment and equity ownership with Adaptive Biotechnologies. HS Robins has employment, equity ownership, patents, and royalties with Adaptive Biotechnologies. HJ Zahid and JM Carlson have employment and equity ownership with Microsoft.
Funding Statement
This work was supported by the Veneto region and was jointly funded by the UK Medical Research Council (MRC; grant MR/R015600/1), the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, the Abdul Latif Jameel Foundation, the Fondazione Umberto Veronesi, Misura Ricerca Covid 19, year 2020, and is also part of the EDCTP2 programme supported by the European Union. E.L. acknowledges funding from the University of Padova and the Department of Molecular Medicine (STARS-CoG ISS-MYTH and PRID/SID 2020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The first sampling of the Vo' population was conducted within the surveillance programme established by the Veneto region and did not require ethical approval; the remaining sampling was approved by the Ethics Committee for Clinical Research of the province of Padua. Study participation was by consent. For participants under 18 years of age, consent was provided by a parent or legal guardian.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added additional authors and updated affiliations. Shortened title and other text changes to fit journal format. Revised introduction including new Figure 1 overview. Added additional serology data and neutralizing antibody titer analysis (updated Figure 2, new Figure 3, new supplemental figures).
Data Availability
Clinical data for this cohort (as described in Lavezzo 2020) is available at https://github.com/ncov-ic/SEIR_Covid_Vo. T-cell repertoire profiles are available as part of the ImmuneCODE data resource (Nolan 2020), and can be downloaded from the Adaptive Biotechnologies immuneACCESS site under the immuneACCESS Terms of Use at https://clients.adaptivebiotech.com/pub/covid-2020.
